La catena delle opzioni mostra i dati chiave delle opzioni azionarie di OneMedNet a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per OneMedNet..

OneMedNet (NASDAQ:ONMDW) Azioni, Catena delle Opzioni

OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real-World Data or iRWDTM. OneMedNet's innovative solutions connect healthcare providers and patients satisfying a crucial need within the Life Sciences field offering direct access to clinical images and the associated contextual patient record.

OneMedNet Corp

Oppenheimer analyst Rick Schafer maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Outperform and lowers the price target from $330 to $300.

News

Price Target

Analyst Ratings

NXPI

Oppenheimer Maintains Outperform on NXP Semiconductors, Lowers Price Target to $300

FREYR Battery (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FREY#NYSE">FREY</a>) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent.

Earnings

Earnings Misses

FREY

FREYR Battery Q3 2024 GAAP EPS $(0.20) Misses $(0.18) Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) with a Buy and maintains $35 price target.

Reiteration

STOK

HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price Target

WIIM

PACS

PACS Group shares are trading lower after the company announced postponement of Q3 results and disclosure on civil investigative demands from the federal government.

Guidance

Freyr Provides 2025 EBITDA Guidance Of $75M - $125M, Expects To Exit 2025 At Full-year Run Rate EBITDA Of $175M - $225M

Freyr Battery Announced An Agreement To Acquire The U.S. Solar Manufacturing Assets Of Trina Solar Co Ltd. For Total Consideration Of $340M

National Vision Holdings Reiterates FY24 Outlook: Sees Revenues Of $1.820B-$1.840B Vs. $1.840B Estimate, With Adjusted EPS Of $0.45 - $0.50 Vs. $0.48 Estimate

Katapult Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>) sees Q4 sales to be up 5 to 7% year-over-year.

KPLT

Katapult Holdings Sees 5 to 7% year-over-year increase in revenue for Q4.

PACS Group Preliminary Q3 Total Facilities Occupancy 90.5%, Expects To Have Ended Quarter With More Than $600M Of Cash And Available Liquidity

2024 EARNINGS GUIDANCE
LXP now estimates that its net income attributable to common shareholders for the year ended December 31, 2024 will be within an expected range of $0.14 to $0.15 per diluted common share. LXP is tightening its estimated Adjusted Company FFO for the year ended December 31, 2024, to be within an expected range of $0.63 to $0.64 per diluted common share. This guidance is forward looking, excludes the impact of certain items and is based on current expectations.

LXP Industrial Trust Narrows FY24 AFFO Guidance from $0.62-$0.65 to $0.63-$0.64 vs $0.63 Est

PACS Group Reveals Postponement Of Release Of Q3 Results; Says It Received Civil Investigative Demands From Federal Government Regarding Reimbursement And Referral Practices

LXP Industrial Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXP#NYSE">LXP</a>) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 11.11 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $85.57 million which beat the analyst consensus estimate of $84.98 million by 0.69 percent. This is a 0.17 percent increase over sales of $85.42 million the same period last year.

Earnings Beats

LXP Industrial Trust Q3 AFFO $0.16, Inline, Sales $85.57M Beat $84.98M Estimate

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) with a Buy and maintains $29 price target.

NRIX

Needham Reiterates Buy on Nurix Therapeutics, Maintains $29 Price Target

Contracts

Tutor Perini, In A Joint Venture With O&G Industries, Has Been Identified As The Apparent Selected Proposer By The New York City Department Of Design And Construction For The New Manhattan Jail Facility

Needham analyst Quinn Bolton maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and lowers the price target from $96 to $85.

MCHP

Needham Maintains Buy on Microchip Technology, Lowers Price Target to $85

Management

IRBT

iRobot Chief Financial Officer Julie Zeiler To Retire, Effective December 2, 2024; Karian Wong To Succeed Zeiler As Finance Chief

Health Care

General

ENOV

Enovis Expects 2024 Adjusted EPS Of $2.75-$2.80 Versus Prior Expectations Of $2.62-$2.77 And Consensus Of $2.71

National Vision Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.06 by 100 percent. The company reported quarterly sales of $451.515 million which beat the analyst consensus estimate of $451.469 million by 0.01 percent. This is a 2.89 percent increase over sales of $438.820 million the same period last year.

National Vision Holdings Q3 2024 Adj. EPS $0.12 Beats $0.06 Estimate, Sales $451.515M Beat $451.469M Estimate

Enovis Narrowed Its Revenue Range And Adjusted  EBITDA  Expectations For 2024, With Sales Estimated At $2.1B Vs. $2.11B Est. And Adjusted EBITDA Of $373M-$378M Versus Prior Guidance Of $368M-$383M

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) with a Buy and maintains $140 price target.

PCVX

Needham Reiterates Buy on Vaxcyte, Maintains $140 Price Target

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OneMedNet

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Schrodinger

Simulations Plus

Sophia Genetics

TruBridge

Teladoc Health

Veeva Systems

VSee Health

Waystar Holding

Comments

OneMedNet

OneMedNet (ONMDW) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO